Axsome v. Alkem, Hetero & Hikma: Sunosi Patent Suit Consolidated in 8 Days
Axsome Malta and Axsome Therapeutics pursued seven Orange Book patents covering Sunosi (solriamfetol) oral tablets against four generic manufacturers — Alkem, Hetero, Hikma, and Aurobindo — in New Jersey federal court. Case No. 24-9209 was consolidated into the sprawling Main Action within eight days of filing, signalling coordinated ANDA litigation strategy across multiple related suits.
Axsome’s multi-front ANDA campaign consolidates into one Sunosi battleground
On September 16, 2024, Axsome Malta Ltd. and Axsome Therapeutics, Inc. filed Civil Action No. 2:24-cv-09209 in the District of New Jersey against Alkem Laboratories Ltd., Hetero Labs Ltd., Hetero USA Inc., Aurobindo Pharma Limited, Aurobindo Pharma USA Inc., and Hikma Pharmaceuticals USA Inc. The complaint alleged infringement of seven U.S. patents listed in the FDA Orange Book for Sunosi® (solriamfetol) oral tablets in 75 mg and 150 mg base-equivalent strengths — patents covering compositions and methods associated with the wakefulness-promoting drug approved for excessive daytime sleepiness.
The case was terminated on September 24, 2024 — just eight days after filing — when Axsome and all defendants jointly requested consolidation into the Main Action (Case No. 23-20354), which had been pending since September 13, 2023. The basis of termination was consolidation, not dismissal or settlement, meaning all claims, parties, and patents from this action were absorbed into the consolidated proceeding. No independent merits ruling was issued in this case number.
The eight-day lifespan reflects a well-coordinated litigation architecture rather than any substantive resolution: Axsome filed several related actions across mid-2024 as new defendants or new patent grants emerged, then promptly consolidated them. The public record for this case number does not disclose underlying licensing negotiations, claim construction positions, or any Paragraph IV certification details. The substantive battleground — validity, infringement, and potential 30-month stays — plays out entirely in the consolidated Main Action.
Filing to Case Consolidated in 8 days
8 days from filing to consolidation — among the shortest ANDA case lifespans in D.N.J.
Case consolidated into Main Action: what this means for both sides
Consolidation under Rule 42: one docket, one schedule
Federal Rule of Civil Procedure 42(a) allows a court to consolidate actions involving common questions of law or fact. Here, all parties jointly requested consolidation, suggesting agreement that efficiency favours a single proceeding. The individual case number (24-9209) is administratively closed, but all claims survive and proceed under the Main Action docket. No claims are extinguished; the litigation clock continues.
Rule 42(a) consolidationAxsome retains all seven patent claims in the consolidated action
Consolidation preserves Axsome’s full assertion posture across all seven Orange Book patents. By centralising multiple related ANDA suits, Axsome may benefit from unified claim construction rulings, coordinated expert discovery, and a single injunction proceeding. The 30-month stay mechanism under Hatch-Waxman continues to run from the date of the earliest Paragraph IV notice letters, protecting Sunosi’s market exclusivity window during the consolidated proceedings.
Full assertion posture preservedDefendants face coordinated multi-patent defence across one forum
For Alkem, Hetero, Hikma, and Aurobindo, consolidation means facing Axsome’s seven-patent portfolio in a single coordinated proceeding with shared discovery and scheduling. While consolidation can create efficiencies, defendants must align their invalidity and non-infringement arguments across a broader patent set. Any adverse claim construction ruling in the Main Action will apply equally to all consolidated defendants, raising the stakes of early motion practice.
Shared discovery riskSunosi’s generic entry timeline hinges on the Main Action outcome
Solriamfetol addresses a commercially significant narcolepsy and sleep-apnea-related excessive daytime sleepiness market. With seven Orange Book patents and four generic challengers consolidated into one proceeding, the outcome of the Main Action will set the effective generic entry date for all ANDA filers simultaneously. A successful defence by any defendant could open the market to multiple generics concurrently, compressing Axsome’s branded revenue runway significantly.
Generic entry date at stakeFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Axsome Malta, Ltd. | Company | Pharmaceutical IP holding and commercial entity — holder of US12064411B1 and 6 further Sunosi patentsSearch in Eureka ↗ |
| Co-Plaintiff | Axsome Therapeutics, Inc. | Company | Search in Eureka ↗ |
| Defendant | Alkem Laboratories, Ltd. | Company | Generic pharmaceutical manufacturers filing ANDA applications for solriamfetol oral tabletsSearch in Eureka ↗ |
| Co-Defendant | Hetero Labs, Ltd. | Company | Search in Eureka ↗ |
| Co-Defendant | Hetero USA, Inc. | Company | Search in Eureka ↗ |
| Co-Defendant | Hetero Labs Limited | Individual | Search in Eureka ↗ |
| Co-Defendant | Aurobindo Pharma Limited, Inc. | Company | Search in Eureka ↗ |
| Co-Defendant | Aurobindo Pharma USA, Inc. | Company | Search in Eureka ↗ |
| Co-Defendant | Hikma Pharmaceuticals USA, Inc. | Company | Search in Eureka ↗ |
| Plaintiff counsel | Alexander Lee Callo | Attorney | Counsel for Axsome Malta, Ltd.Search in Eureka ↗ |
| Plaintiff counsel | Charles Michael Lizza | Attorney | Counsel for Axsome Malta, Ltd.Search in Eureka ↗ |
| Plaintiff counsel | Sarah Ann Sullvian | Attorney | Counsel for Axsome Malta, Ltd.Search in Eureka ↗ |
| Plaintiff counsel | William C. Baton | Attorney | Counsel for Axsome Malta, Ltd.Search in Eureka ↗ |
| Plaintiff law firm | Saul Ewing LLP | Law Firm | Representing Axsome Malta, Ltd.Search in Eureka ↗ |
| Defendant counsel | Rebekah R. Conroy | Attorney | Counsel for Alkem Laboratories, Ltd.Search in Eureka ↗ |
| Defendant law firm | Stone Conroy LLC | Law Firm | Representing Alkem Laboratories, Ltd.Search in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | New Jersey District CourtSearch in Eureka ↗ |
Official order — verbatim text
The consolidation order reflects a procedural disposition rather than any merits adjudication. The verdict text confirms that all defendants jointly requested consolidation alongside Axsome, suggesting no party opposed the move — consistent with a shared interest in resolving seven overlapping patent assertions on a single coordinated track. No infringement finding, invalidity ruling, or damages determination was made in this case number. The substantive dispute over Sunosi’s Orange Book patents remains live in the Main Action (23-20354), where claim construction, expert discovery, and potentially trial will determine the outcome for all parties.
US12064411B1 and six further patents — Sunosi (solriamfetol) oral tablet formulations
The seven asserted patents — US12064411B1, US11986455B2, US11998639B2, US12036194B1, US11986454B1, US12005036B1, and US11969404B2 — are all listed in the FDA Orange Book for Sunosi® (solriamfetol), a dopamine and norepinephrine reuptake inhibitor approved for excessive daytime sleepiness associated with narcolepsy and obstructive sleep apnea. The corrected application numbers suggest a programme of continuation and divisional filings across 2022–2023, indicating a deliberate strategy to build layered patent protection around the solriamfetol franchise as ANDA activity intensified.
For the CNS and sleep medicine sector, these patents collectively represent a significant exclusivity barrier for generic solriamfetol entry. The multi-patent Orange Book listing means that any ANDA filer submitting a Paragraph IV certification against any listed patent triggers a 45-day window for Axsome to sue and invoke the automatic 30-month stay. With four major generic manufacturers now consolidated into one proceeding, the outcome of the Main Action will function as an industry-wide determination of whether generic solriamfetol can enter the market — making this one of the higher-stakes ANDA battles currently proceeding in D.N.J.
Should you run an FTO against Axsome’s solriamfetol patent portfolio?
Any company developing solriamfetol formulations, dopamine-norepinephrine reuptake inhibitor (DNRI) compositions, or wakefulness-promoting CNS drug products should treat Axsome’s seven-patent Orange Book cluster as a live freedom-to-operate concern. The portfolio spans multiple application families and includes both composition and method-of-use claims, meaning route-of-administration or dosing innovations may not avoid infringement without careful claim-by-claim analysis. Generic manufacturers, contract development organisations, and branded CNS drug developers all face exposure.
PatSnap Eureka’s FTO Search Agent allows you to map each of the seven asserted patents against your product’s formulation parameters, dosing regimen, and method of manufacture in a single workflow. Eureka surfaces relevant prior art, identifies claim scope boundaries, and flags continuation applications that may not yet appear in Orange Book listings — giving R&D and IP teams an early-warning system before ANDA filing or product launch decisions are made.
Run a freedom-to-operate analysis on US12064411B1 to assess your product’s exposure
Run FTO in Eureka →Similar Hatch-Waxman ANDA cases: CNS drug patent enforcement in D.N.J.
These cases share key features with the Axsome Sunosi litigation: Orange Book patent assertions, ANDA-triggered infringement claims, and consolidation of multi-defendant proceedings in D.N.J.
What this case signals for the Hatch-Waxman and CNS drug IP landscape
Axsome’s rapid-fire filing and consolidation strategy is a textbook illustration of modern ANDA patent enforcement — and a warning for generic entrants.
Serial ANDA filings drive multi-case consolidation as an enforcement tool
Axsome filed at least seven related actions across 2023–2024 as new defendants sought approval and new patents issued. This rolling-filing approach, followed by consolidation, maximises the Hatch-Waxman 30-month stay while keeping all challengers on a unified timeline. Generic manufacturers monitoring CNS drug pipelines should expect this pattern from branded holders with expanding Orange Book listings.
Seven-patent Orange Book listings raise the invalidity burden for generics
With seven patents listed for a single drug product, ANDA challengers face staggered expiry dates and layered invalidity challenges. Even if generics succeed against some patents, surviving patents may extend market exclusivity. R&D teams developing competing solriamfetol formulations should map each patent’s claims independently — a single surviving patent can delay launch by years.
Axsome v Alkem — key questions answered
Case No. 2:24-cv-09209 was filed on September 16, 2024 by Axsome Malta Ltd. and Axsome Therapeutics, Inc. against Alkem, Hetero, Hikma, and Aurobindo over seven Orange Book patents covering Sunosi (solriamfetol) tablets. The case was terminated on September 24, 2024 — eight days after filing — by consolidation into the Main Action (23-20354) at the joint request of all parties. No merits ruling was issued.
Axsome asserted seven U.S. patents listed in the FDA Orange Book for Sunosi (solriamfetol): US12064411B1, US11986455B2, US11998639B2, US12036194B1, US11986454B1, US12005036B1, and US11969404B2. These patents cover compositions and methods related to solriamfetol oral tablets in 75 mg and 150 mg base-equivalent strengths used to treat excessive daytime sleepiness.
Consolidation under Federal Rule of Civil Procedure 42(a) merges multiple related actions sharing common questions of law or fact into a single proceeding. In ANDA litigation, this is common when a brand-name holder files separate suits against multiple generic filers. Consolidation does not extinguish any claims — it centralises discovery, scheduling, and ultimately trial or settlement under one docket, typically the earliest-filed Main Action.
The defendants in the consolidated Sunosi ANDA litigation include Alkem Laboratories Ltd., Hetero Labs Ltd. and affiliated Hetero entities, Hikma Pharmaceuticals USA Inc., and Aurobindo Pharma Limited and Aurobindo Pharma USA Inc. Sandoz Inc. and Unichem Laboratories Ltd. were previously dismissed from the Main Action before this case was filed.
Case No. 2:24-cv-09209 is closed by virtue of consolidation. The underlying litigation is ongoing in the Main Action, Case No. 23-20354, in the District of New Jersey. That consolidated proceeding covers all seven Orange Book patents for Sunosi and all remaining defendants, and as of the public record available at the time of this case’s consolidation, no final merits judgment had been entered in the Main Action.
PatSnap Eureka searches patents and litigation data to answer instantly.